Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir | Scientific Reports
Advances in Treatment of Hepatitis C | IntechOpen
Viruses | Free Full-Text | Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
Sofosbuvir/velpatasvir: A promising combination
Plant Uptake and Metabolism of 2,4-Dibromophenol in Carrot: In Vitro Enzymatic Direct Conjugation | Journal of Agricultural and Food Chemistry
Sofosbuvir-Velpatasvir Epclusa - Treatment - Hepatitis C Online
Structure-activity relationships of fluorene compounds inhibiting HCV variants - ScienceDirect
Antivirals for Hepatitis C | Concise Medical Knowledge
Learning the ABC's of Today's Hepatitis C Medications
Cells | Free Full-Text | Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence
Evolution of efficacious pangenotypic hepatitis C virus therapies - Ashraf - 2019 - Medicinal Research Reviews - Wiley Online Library
Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
Sofosbuvir/Velpatasvir/Voxilaprevir: A Highly Effective Option for Retreatment of Hepatitis C in Difficult-to-treat Patients - Poonam Mathur, Shyamasundaran Kottilil, Eleanor Wilson, 2019
PathWhiz
Frontiers | Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
Velpatasvir - an overview | ScienceDirect Topics
Sofosbuvir - Wikipedia
Frontiers | Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects
Viruses | Free Full-Text | Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
Cells | Free Full-Text | Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India | PLOS ONE
Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant | ACS Omega
Sofosbuvir, a Significant Paradigm Change in HCV Treatment
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update | SpringerLink
Recent advances in managing chronic HCV... | F1000Research
